Inhibition of c-FLIP alongside TRAIL treatment suppresses prostate cancer stem cell activity
Inhibition of cFLIP in combination with either TRAIL or docetaxel has the potential to be used as a novel therapeutic approach to provide more potent, long-lasting benefits to men with prostate cancer.
Authors
- Fiona M. Frame (ORCID: https://orcid.org/0000-0002-2377-1110)
- Daniel J. Turnham (ORCID: https://orcid.org/0000-0002-2540-7363)
- Rhiannon French
- Valérie S. Méniel
- Norman J. Maitland (ORCID: https://orcid.org/0000-0003-1607-9035)
- R. Clarkson
Institutions
- University of the West of England (GB)
- Yorkshire Cancer Research (GB)
- Cardiff University (GB)
- Cardiff Metropolitan University (GB)
Publication Details
- Journal
- British Journal of Cancer
- Published
- 2026-03-03
- DOI
- https://doi.org/10.1038/s41416-026-03359-4
- Primary Topic
- Cell death mechanisms and regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Cardiff University